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Background: We measured biomarkers of tumour growth and vascularity in interval and screen-detected colorectal
cancers (CRCs) in the English Bowel Cancer Screening Programme in order to determine whether rapid tumour growth
might contribute to interval CRC (a CRC diagnosed between a negative guaiac stool test and the next scheduled screening
episode).
Methods: Formalin-fixed, paraffin-embedded sections from 71 CRCs (screen-detected 43, interval 28) underwent immunohis-
tochemistry for CD31 and Ki-67, in order to measure the microvessel density (MVD) and proliferation index (PI), respectively, as
well as microsatellite instability (MSI) testing.
Results: Interval CRCs were larger (P¼ 0.02) and were more likely to exhibit venous invasion (P¼ 0.005) than screen-detected
tumours. There was no significant difference in MVD or PI between interval and screen-detected CRCs. More interval CRCs
displayed MSI-high (14%) compared with screen-detected tumours (5%). A significantly (P¼ 0.005) higher proportion (51%) of
screen-detected CRC resection specimens contained at least one polyp compared with interval CRC (18%) resections.
Conclusions:We found no evidence of biological differences between interval and screen-detected CRCs, consistent with the low
sensitivity of guaiac stool testing as the main driver of interval CRC. The contribution of synchronous adenomas to occult blood
loss for screening requires further investigation.
The NHS Bowel Cancer Screening Programme (BCSP), based on
biennial guaiac-based faecal occult blood testing (gFOBt), was
introduced in England in 2006 with the aim of reducing mortality
from colorectal cancer (CRC) by 16% (West et al, 2008). Interval
CRC (defined as a CRC diagnosed within the 2-year window
between a negative gFOBt episode and the next scheduled
screening episode) is a well-recognised outcome in all studies of
population-based gFOBt programmes and accounts for 30–60% of
all CRC diagnoses in a screened population depending on the
screening round (Morris et al, 2012). Interval CRCs are more
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common in women and occur more frequently in the proximal
colon (proximal to the splenic flexure) compared with screen-
detected CRCs (Gill et al, 2012; Steele et al, 2012).
It has been assumed that the majority of interval CRCs
represent missed lesions related to false-negative gFOBt or missed
colorectal neoplasia at colonoscopy. However, an alternative
explanation is that differences in the biology of individual tumours
allow rapid interval CRC growth between biennial screening
episodes. We recently reported that patients with a screen-detected
CRC have improved survival compared with individuals with a
stage-matched interval CRC (Gill et al, 2014). Although lead-time
bias cannot be excluded, these data further support the hypothesis
that interval CRCs are biologically more aggressive and/or have
less propensity to bleed (explaining the lack of gFOBt positivity).
Moreover, interval CRCs in colonoscopic screening programmes
are more likely to demonstrate microsatellite instability (MSI)
(Sawhney et al, 2006), a feature associated with accelerated
colorectal carcinogenesis in the setting of Lynch syndrome
(Rubenstein et al, 2015).
Therefore, we compared biomarkers of tumour growth and
vascularity in interval and screen-detected CRCs in order to
determine whether tumour factors explain whether a given CRC is
detected by a gFOBt screening episode or is diagnosed between
screening episodes.
MATERIALS AND METHODS
Patient and CRC cohort. Approval was obtained from the
London—Central Research Ethics Committee. A random sample
of CRC cases were taken from The Northern Region Colorectal
Cancer Audit Group (NORCCAG) cohort which had been
previously used to determine differences between screen-detected
(from the first, prevalent screening round) and interval CRCs (Gill
et al, 2012). The CRCs were all diagnosed from 1 April 2007 to 31
March 2010 in the patients aged 60–69 years. To determine
screening status, the cohort was cross-referenced with the regional
BCSP database to gather information on gFOBt invitations and
results, screening appointments and colonoscopies. An interval
cancer was defined as a CRC, which was diagnosed between a
negative gFOBt screening episode and before the next scheduled
screening episode. A screen-detected CRC was defined as a case
diagnosed through the English BCSP. This study did not include
post-colonoscopy CRCs.
Archival formalin-fixed, paraffin-embedded CRC specimens
and the corresponding anonymised histopathology report were
obtained from three hospitals (North Tyneside General Hospital,
South Tyneside General Hospital and Royal Victoria Infirmary,
Newcastle upon Tyne, UK). A ratio of 2–3 screen-detected CRCs to
one interval CRC was maintained across the study cohort in order
to mirror the ratio of screen-detected to interval CRC cases
observed in the full NORCCAG cohort. The following data were
collected from the histopathology report, with all investigators
blinded as to whether each CRC was screen-detected or an interval
tumour; site of the CRC in the colorectum (proximal or distal to
the splenic flexure), size, ulcerative morphology, Dukes’ Stage,
histological differentiation grade, draining lymph node involve-
ment, presence of additional polyps, extramural venous invasion,
lymphatic invasion. All analyses were performed blinded to the
categorisation (screen-detected vs interval) of the CRC specimen.
A sample size of 70 CRCs was chosen on the basis of a previous
CD31 microvessel density (MVD) angiogenesis study, which
reported a relationship between tumour MVD and clinical
outcomes in primary CRC patients (Rajaganeshan et al, 2007).
Tumour histological analysis. CRC blocks were sectioned (5mm
thickness) using a Leica RM2255 microtome (Milton Keynes, UK).
Sections were mounted on Thermo Scientific Superfrost Plus slides
(Waltham, MA, USA) and left to dry for 24 h at 37 1C. A
haematoxylin and eosin-stained section from each block was
prepared and used to identify the orientation of the tissue including
the luminal border of the tumour. For cases with more than one CRC
block, a single block was chosen for further analysis based on
subjective analysis of each haematoxylin and eosin section (at  100
magnification) for the presence of the highest-quality malignant
tissue with orientation perpendicular to the luminal surface such that
the maximum amount of luminal (often eroded) surface was
available for vascular ‘hotspot’ counting (see below).
Immunohistochemistry for CD31. After dewaxing in xylene and
rehydration in an ethanol series, slides were washed in running tap
water. The slides were heated for 10min in 10mM citric acid buffer
(pH 6.0) using a 900W microwave, left to cool for 20min, then
placed under running tap water. Slides were added to 0.3% (v/v)
hydrogen peroxide solution in 100% methanol for 10min. They
were then rinsed in tap water for 5min. Non-specific binding was
blocked with Invitrogen (Thermo Fisher Scientific, Waltham, MA,
USA) antibody diluent and then a 1 : 20 dilution of mouse
monoclonal anti-CD31 (clone JC70A (Dako UK Ltd, Ely, UK) in
antibody diluent was added for 1 h at room temperature. Following
washes with tris-buffered saline plus 0.025% (v/v) Tween 20 and
tris-buffered saline alone, immunoreactivity was visualised using a
mouse EnVision detection kit and counterstained with haematox-
ylin before mounting with DPX (Sigma-Aldrich, Dorset, UK).
Microvessel density analysis. Image analysis was performed by
one individual (EW) using the Nikon Eclipse (Nikon UK Ltd.,
Kingston upon Thames, UK) E1000 microscope and NIS-Elements
software (Nikon UK Ltd.). Three vascular ‘hotspots’ were identified
on each slide. A ‘hotspot’ was defined as a high-power field ( 200
magnification; 0.28mm2) contained within a  100 magnification
field that included luminal tumour surface (to ensure that the
surface vasculature that was analysed is the most relevant to
luminal blood loss), which contained the maximum number of
CD31-positive vascular structures. The MVD in vessels per mm2
was determined. If a section was deemed to have less than three
vascular ‘hotspots’, the ‘missing hotspot’ was scored zero. In each
case, the mean MVD per section was calculated. Repeat analysis
(n¼ 4) by the same operator generated coefficients of variation of
2% (low MVD) and 13% (high MVD).
Immunohistochemistry for Ki-67. Mouse monoclonal anti-Ki-67
(clone MIB1) antibody (Dako, Dako UK Ltd) was used to identify
proliferating malignant epithelial cells by immunohistochemistry
as described above except that slides were heated for 2min in
antigen retrieval buffer and antigen unmasking solution (both from
Vector Laboratories, CA, USA) using a pressure cooker. A 1 :50
dilution of primary antibody in Invitrogen antibody diluent was
incubated with slides for 1 h at room temperature.
Measurement of the tumour proliferation index. Each section
was scanned at  100 magnification and a high-power field
( 400; 0.07mm2) containing all tumour tissue and a minimum
200 malignant epithelial cells was chosen. If a slide did not fit these
criteria, it was excluded from the analysis. The total number of
stained and unstained epithelial cells was counted and the %
proliferation index (PI) was calculated as the number of positive
cells divided by the total number of epithelial cells.
Microsatellite instability testing. MSI analysis was carried out by
the Northern Molecular Genetics Service (Centre for Life, New-
castle Upon Tyne, UK) on 2 10 mm thick curls from each tumour
block using the Promega MSI analysis system v1.2 (Promega UK,
Southampton, UK), which analyses five mononucleotide repeat
markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27). MSI-
high was defined as alteration in X2 markers.
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Statistical analysis. Student’s t-test was used to compare con-
tinuous variables between the two CRC groups. The w2-test or
Fisher’s exact test was used to compare categorical variables
between the two groups. All analyses were performed using
Stata v13.0 (StataCorp, College Station, TX, USA).
RESULTS
Archival tissue and the accompanying histopathology report for 98
CRCs were collected from three NORCCAG sites. Two cases were
excluded on the basis that one was a secondary neoplasm from a
non-CRC primary cancer and another case had multiple primary
CRCs. Another archival CRC specimen was excluded as it was a
duplicate of one of the CRC specimens. We next excluded ‘polyp
cancers’ (n¼ 24) in which the primary tissue was adenoma, from
which a focus of cancer had developed (exclusively screen-detected
lesions), on the basis that the pathology and bleeding behaviour of
a benign adenoma is likely to be different to an established
malignant CRC, thus confounding comparison of biomarkers of
tumour growth and bleeding tendency. Therefore, we analysed 71
non-polyp (screen detected n¼ 43; interval n¼ 28) CRCs.
Clinico-pathological characteristics of screen-detected and
interval CRCs are described in Table 1. Interval CRCs were larger
(P¼ 0.02) and were more likely to exhibit histological venous
invasion (P¼ 0.005) than screen-detected tumours, although
tumours were well matched for Dukes’ stage (Table 1). The two
groups were well matched regarding tumour location and
histological differentiation grade, with 67% and 57% of tumours
located distal to the splenic flexure in screen-detected and interval
CRCs, respectively (P¼ 0.38). We were particularly interested in
the presence of ulceration in individual CRCs as this may relate to
bleeding propensity. We did not detect any difference in the
proportion of screen-detected (56%) or interval CRCs (44%) that
were reported to exhibit ulcerating morphology in the histopathol-
ogy report. Interval CRCs in colonoscopy screening and surveil-
lance programmes have been reported to be more likely to exhibit
MSI (Sawhney et al, 2006). In our study, we did not observe a
significant difference in the proportion of MSI-high tumours
between screen-detected (5%) and interval (14%) CRCs, although
there was a numerical excess of MSI-high tumours in the interval
CRC group. However, our study was underpowered to detect a
significant difference, perhaps related to the relatively small
number of proximal CRCs in the interval CRC group.
There was a wide range of tumour MVD values in both the
groups, which mirrors known heterogeneity in CRC MVD values
(Wang et al, 2014) (Table 2 and Figure 1). There was no significant
difference in MVD values between screen-detected and interval
CRCs (Table 2 and Figures 1A–C) suggesting no difference in
vascularity of the two tumour groups. Similarly, there was no
difference in the tumour PI between screen-detected and interval
CRCs (Table 2 and Figures 1D–F), with the mean PI value for both
groups in concordance with previous data in primary CRCs (Fodor
et al, 2012).
We were also interested to note other pathology present in the
surgical CRC resection specimens including synchronous color-
ectal polyps. Interestingly, there was a significantly higher
proportion (51%) of screen-detected CRC resection specimens
that contained at least one additional colorectal polyp compared
with the corresponding interval CRC specimens (18%; Table 1).
Importantly, the length of colectomy specimens in each group was
similar (Table 3). More detailed analysis of polyp characteristics
determined that there were 44 polyps detected in 22 screen-
detected CRC resection specimens compared with eight polyps in
five interval CRC resection specimens (Table 3). The histological
type and multiplicity of polyps in the two groups were similar,
although polyps detected in screen-detected CRC specimens were
larger than interval CRC resection specimen counterparts
(P¼ 0.07; Table 3).
Table 1. Characteristics of screen-detected and interval CRCs
Screen-detected CRC
(n¼43)
Interval CRC
(n¼28) P-value
Site (number (%)) 0.38
Distal to splenic flexure 29 (67) 16 (57)
Proximal to splenic flexure 14 (33) 12 (43)
Size (maximum dimension in mm, mean (range)) 36 (11–70) 44 (18–80) 0.02
Ulcerating morphology (number (%))a 20 (56) 11 (44) 0.17
Dukes’ stage (number (%))b 0.73
A 5 (12) 6 (21)
B 16 (39) 8 (29)
C 20 (49) 14 (50)
Differentiation grade (number (%))c 0.54
Well 7 (16) 7 (25)
Moderate 32 (75) 16 (56)
Poor 4 (9) 5 (19)
Extramural venous invasion (yes/no (%))d 4 (10)/37 (90) 11 (42)/15 (58) 0.005
Additional polyp(s) (present : absent (%)) 22 (51) : 21 (49) 5 (18) : 23 (82) 0.005
MSI status (stable/low : high (%)) 41 (95) : 2 (5) 24 (86) : 4 (14) 0.20
Abbreviations: CRC¼ colorectal cancer; MSI¼microsatellite instability.
aSeven (screen) and three (interval) cases not known.
bNot known for two cases in the screen-detected group.
c‘Well’ includes well and well to moderate, ‘poor’ includes poor and moderate to poor.
dTwo cases not known in each CRC category.
Table 2. Biomarkers of CRC vascularity and growth
Screen-detected
CRC (n¼43)
Interval CRC
(n¼28) P-value
Microvessel density
(mean (s.d.) : range)
96 (7) : 0–203 95 (8) : 32–188 0.52
Proliferation index
(mean (s.d.) : range)a
70.5 (2.7) : 30.7–93.1 66.5 (4.2) : 15.1–92.5 0.80
Abbreviation: CRC¼ colorectal cancer.
an¼ 40 (screen) and n¼ 28 (interval) for Ki-67 IHC due to lack of archival FFPE tissue.
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DISCUSSION
Understanding the biological characteristics of CRCs may improve
the understanding of differences between screen-detected and
interval cancers. Our previous study demonstrated improved
outcomes in screen-detected patients with differences in biological
characteristics provided as a possible explanation. In this study, we
therefore sought to explore various characteristics of screen-
detected and interval CRCs. We did not demonstrate any
difference in vascularity (measured by CD31-positive MVD) or
tumour growth rate (measured by Ki-67 PI) between screen-
detected and interval ‘non-polyp cancer’ CRCs in the English
BCSP.
It is a plausible hypothesis that differences in tumour bleeding
propensity contribute to the detection of CRCs by the BCSP. We
used immunohistochemistry for CD31 and vascular ‘hotspot’
counting as the most established methods for quantifying tumour
vascularity (Wang et al, 2014). The degree of tumour surface
erosion and ulceration may be critical to blood loss from a CRC
(Hirano et al, 1996). However, we were unable to determine the
degree of surface erosion and ulceration in archival fixed CRC
tissue, which was only available retrospectively, often in multiple
blocks. A frequent finding in CRC resection specimens is vascular
congestion with blood engorgement of tumour vessels. However,
this phenomenon is likely to be an artefact related to clamping of
colorectal vasculature at surgery. Therefore, we did not attempt to
measure vessel size or vascular congestion.
We did not provide any evidence that interval CRCs have a
faster growth rate than screen-detected tumours based on the Ki-
67 PI. Therefore, the increased size and venous invasion observed
in interval CRCs are most likely to be explained by longer lead time
prior to diagnosis, rather than increased ‘aggressiveness’ of interval
CRCs. The excess of interval CRCs in the proximal colon and
higher proportion of MSI in interval CRCs in our study is
consistent with previous reports and suggests that our CRC series
is representative of screen-detected and interval CRCs from other
screening programmes (Sawhney et al, 2006; Steele et al, 2012; Gill
et al, 2014).
A provocative finding was the increased prevalence of polyps in
screen-detected CRC resection specimens compared with interval
CRC resection specimens. This is despite the fact that individuals
undergoing colorectal surgery for a screen-detected CRC were
more likely to have undergone colonoscopy and polypectomy than
A B C
D E F
Figure 1. Immunohistochemistry for CD31 and Ki-67. (A–C) Examples of CRC ‘hotspots’ with high, medium and low MVD, respectively. Arrows
highlight two of the vessels in each case. All images were captured at  200 magnification. D–F, examples of CRCs with a high, medium and low PI
respectively. All images were captured at 400 magnification.
Table 3. Characteristics of polyps found in surgical resection specimens of screen-detected and interval CRCs
Screen-detected CRC
(n¼22)
Interval CRC
(n¼5) P-value
Total number of polyps 44 8 –
Length of resection specimen (mm, mean (range))a 356 (150–1000) 288 (180–530) 0.30
Size (mm, mean (range)) 8 (2–35) n¼40b 5 (3–6) n¼7b 0.07
Site (number (%)) n¼ 42b 0.70
Distal to splenic flexure 21 (50) 3 (38)
Proximal to splenic flexure 21 (50) 5 (63)
Histology (number (%)) n¼7b 0.71
TA 6 (14) 0 (0)
TVA or villous 28 (64) 5 (71)
Hyperplasticc 10 (23) 2 (29)
Abbreviations: CRC¼ colorectal cancer; TA¼ tubular adenoma; TVA¼ tubulovillous adenoma. Total number of additional polyps; screen-detected (n¼ 44), interval (n¼ 8).
aOne (interval) case not known, one (screen-detected) case was colonoscopy finding, size taken as 1000.
bSample number quoted if any data missing.
cHyperplastic denotes hyperplastic or serrated.
BRITISH JOURNAL OF CANCER Biology of interval colorectal cancer
4 www.bjcancer.com |DOI:10.1038/bjc.2016.159
those presenting with a CRC following a negative gFOBt. This
raises the question as to whether synchronous colorectal polyps
contribute to luminal blood loss and gFOBt positivity, over and
above that from established CRCs. Counter-intuitively, intestinal
blood loss from CRCs is intermittent and surprisingly low as
measured by 51Cr loss, being only slightly greater than in patients
with adenomatous polyps (Doran and Hardcastle, 1982; Herzog
et al, 1982). Therefore, blood loss from synchronous polyps may
provide a significant contribution to overall blood loss and
performance of the low-sensitivity gFOBt. Alternatively, synchro-
nous neoplasia may be a surrogate marker of increased ‘field effect’
mucosal microvascular blood content, which might contribute
significantly to faecal blood loss in addition to that from neoplastic
lesions (Roy et al, 2008). However, the number of synchronous
polyps in each CRC group was relatively small, limiting the
strength of any conclusion that can be drawn about a possible
contribution of polyps to intestinal blood loss.
Independent studies have reported that the faecal haemoglobin
concentration measured by the faecal immunochemical test is
higher in CRC patients than those with colorectal adenomatous
polyps and that faecal haemoglobin concentration correlates with
tumour size and location (Ciatto et al, 2007; Digby et al, 2013). It
will be important to perform a similar comparison of screen-
detected and interval CRCs in the proposed faecal immunochem-
ical test-based screening programme in England. The quantitative
faecal immunochemical test will allow a more detailed comparison
of intestinal blood loss between patients with CRC with and
without synchronous adenomatous polyps.
In conclusion, we did not detect any biological difference
between screen-detected and interval CRCs in the English gFOBt-
based BCSP, except for tumour size and venous invasion. This
finding is consistent with low sensitivity of the gFOBt for CRC
detection as the main driver of interval CRC (rather than rapid
growth and/or reduced bleeding propensity) in the English BCSP.
Differences in survival between screen and interval cancer patients
are most likely explained by lead-time bias.
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